Dr Reddy's Labs

{
  "main_header": {
    "sid": 734514,
    "name": "Dr Reddy's Labs",
    "stock_name": "Dr Reddy's Labs",
    "full_name": "Dr Reddys Laboratories Ltd",
    "name_url": "stocks-analysis/dr-reddy-s-labs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,182.35",
    "chg": -0.4,
    "chgp": "-0.03%",
    "dir": -1,
    "prev_price": "1,182.75",
    "mcapval": "99,434.00 Cr",
    "mcap": "Large Cap",
    "scripcode": "500124",
    "symbol": "DRREDDY",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE089A01031",
    "curr_date": "Feb 02",
    "curr_time": "",
    "bse_nse_vol": "12.43 lacs",
    "exc_status": "Active",
    "traded_date": "Feb 02, 2026",
    "traded_date_str": "2026 02 02",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/dr-reddy-s-labs-734514-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Dr Reddys Laboratories Ltd Faces Downgrade Amidst Mixed Market Performance and Nifty 50 Membership Significance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-faces-downgrade-amidst-mixed-market-performance-and-nifty-50-membership-significance-3815891",
        "imagepath": "",
        "date": "2026-02-02 09:20:32",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Index Membership and Market Significance</strong></p>\n                <p>As a key member of the Nifty 50, Dr Reddys Laboratories Ltd holds considerable influence on the benchmark’s overall performance, particularly within the Pharmaceuticals & Biotechnology sector. The company’s market capitalisation stands at a robust ₹99,149.91 crores, underscoring its stature as a large-cap stock. Its inclusion in the index not only attracts passive fund flows from index-tracking funds but also places it under the scrutiny of institutional investors who closely monitor sectoral and market-wide trends.</p>\n                <p>However, the stock’s recent performance has been underwhelming relative to the Sensex and sector peers. Over the past year, Dr Reddys Laboratories has recorded a decline..."
      },
      {
        "title": "Dr Reddys Laboratories Ltd Faces Sell Grade Amid Mixed Performance and Nifty 50 Membership Impact",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-faces-sell-grade-amid-mixed-performance-and-nifty-50-membership-impact-3813878",
        "imagepath": "",
        "date": "2026-02-01 09:20:58",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Significance of Nifty 50 Membership</strong></p>\n                <p>Being part of the Nifty 50 index confers considerable prestige and investment inflows for Dr Reddys Laboratories Ltd. The index membership ensures enhanced visibility among domestic and global institutional investors, often translating into higher liquidity and a more stable shareholder base. However, this status also brings heightened expectations regarding financial performance and corporate governance.</p>\n                <p>Dr Reddys, with a market capitalisation of ₹1,01,666.32 crores, is categorised as a large-cap stock, making it a key component of the index’s Pharmaceuticals & Biotechnology sector representation. The company’s inclusion in the Nifty 50 means that passive funds tracking the index must h..."
      },
      {
        "title": "Dr Reddys Laboratories Ltd Faces Headwinds Amid Nifty 50 Membership and Institutional Shifts",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-faces-headwinds-amid-nifty-50-membership-and-institutional-shifts-3810794",
        "imagepath": "",
        "date": "2026-01-30 09:21:08",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Significance of Nifty 50 Membership</strong></p>\n                <p>As a member of the Nifty 50, Dr Reddys Laboratories Ltd holds a pivotal role in India's benchmark equity index, which represents the top 50 companies by free-float market capitalisation on the National Stock Exchange. Inclusion in this index not only enhances the stock's visibility among domestic and international investors but also ensures substantial passive fund inflows from index-tracking mutual funds and exchange-traded funds (ETFs). This status typically provides a degree of price support and liquidity, making the stock a preferred choice for large institutional portfolios.</p>\n                <p>However, membership also brings heightened scrutiny and expectations. Dr Reddys Laboratories Ltd's recent per..."
      },
      {
        "title": "Dr Reddys Laboratories Ltd Faces Sell Downgrade Amid Nifty 50 Membership Significance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-faces-sell-downgrade-amid-nifty-50-membership-significance-3808937",
        "imagepath": "",
        "date": "2026-01-29 09:20:58",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Significance of Nifty 50 Membership</strong></p>\n                <p>As a key component of the Nifty 50 index, Dr Reddys Laboratories Ltd holds a critical position in India’s equity market landscape. Inclusion in this benchmark index not only enhances the stock’s visibility among domestic and international investors but also ensures substantial liquidity and institutional interest. The company’s market capitalisation stands at a robust ₹1,00,581.30 crores, categorising it firmly as a large-cap stock. This stature typically attracts passive funds tracking the Nifty 50, thereby providing a degree of price support and stability.</p>\n                <p>However, the recent performance metrics indicate that Dr Reddys is struggling to maintain its momentum. The stock has declined by 1..."
      },
      {
        "title": "Dr Reddys Laboratories Ltd: Navigating Nifty 50 Membership Amid Institutional Shifts",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-amid-institutional-shifts-3806945",
        "imagepath": "",
        "date": "2026-01-28 09:21:01",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Index Membership: A Double-Edged Sword</strong></p>\n                <p>Being part of the Nifty 50 index confers Dr Reddys Laboratories Ltd a prestigious status, reflecting its market capitalisation, liquidity, and sector representation. With a market cap of ₹1,03,602.67 crores, it firmly sits among India’s large-cap elite. This membership ensures substantial passive fund inflows, as index-tracking funds and ETFs allocate capital in line with the index composition. However, it also subjects the stock to heightened scrutiny and volatility linked to broader index movements.</p>\n                <p>Dr Reddys’ current valuation metrics reveal a price-to-earnings (P/E) ratio of 18.59, notably below the Pharmaceuticals & Biotechnology sector average of 32.47. This discount suggests th..."
      },
      {
        "title": "Dr Reddys Laboratories Ltd: Navigating Nifty 50 Membership Amid Institutional Shifts",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-amid-institutional-shifts-3805066",
        "imagepath": "",
        "date": "2026-01-27 09:20:57",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Significance of Nifty 50 Membership</strong></p>\n                <p>As a constituent of the Nifty 50, Dr Reddys Laboratories Ltd holds a critical position within India’s premier equity benchmark. Inclusion in this index not only reflects the company’s market capitalisation and liquidity but also ensures substantial institutional interest, particularly from index funds and passive investors. The stock’s market cap currently stands at a robust ₹1,04,036.67 crores, categorising it firmly as a large-cap entity within the Pharmaceuticals & Biotechnology sector.</p>\n                <p>Being part of the Nifty 50 means Dr Reddys is often a bellwether for sectoral and broader market trends. Its performance can influence the sectoral index and, by extension, the overall market sentiment..."
      },
      {
        "title": "Dr Reddys Laboratories Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/dr-reddys-laboratories-ltd-is-rated-sell-3804146",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/DrReddysLaborat_mojoScore_3804146.png",
        "date": "2026-01-25 10:10:04",
        "description": "Dr Reddys Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 14 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 January 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Dr Reddys Laboratories Gains 5.07%: 4 Key Factors Driving the Weekly Move",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-gains-507-4-key-factors-driving-the-weekly-move-3803505",
        "imagepath": "",
        "date": "2026-01-24 16:00:08",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>Jan 19:</strong> Death Cross formation signals bearish trend</p>\n                    <p><strong>Jan 20:</strong> Bearish momentum intensifies amid technical downturn</p>\n                    <p><strong>Jan 21:</strong> Q3 FY26 results reveal margin pressures despite revenue resilience</p>\n                    <p><strong>Jan 22:</strong> Intraday high surge of 4.98% with strong gap up opening</p>\n                    <p><strong>Jan 23:</strong> Week closes at Rs.1,235.15 (+1.48%) outperforming Sensex</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.1,175.55</..."
      },
      {
        "title": "Dr Reddys Laboratories Ltd: Navigating Nifty 50 Membership Amid Mixed Performance and Institutional Shifts",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-amid-mixed-performance-and-institutional-shifts-3801113",
        "imagepath": "",
        "date": "2026-01-23 09:21:09",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Significance of Nifty 50 Membership</strong></p>\n                <p>Being part of the Nifty 50 index confers considerable advantages to Dr Reddys Laboratories Ltd, including enhanced visibility among domestic and global investors, increased liquidity, and inclusion in numerous index-tracking funds and ETFs. This membership not only bolsters the company’s profile but also influences trading volumes and price stability. However, it also subjects the stock to heightened scrutiny and performance expectations relative to peers within the Pharmaceuticals & Biotechnology sector and the broader market.</p>\n\n                <p><strong>Recent Market Performance and Valuation</strong></p>\n                <p>Dr Reddys Laboratories Ltd currently holds a market capitalisation of ₹1,01,587 c..."
      }
    ],
    "total": 458,
    "sid": "734514",
    "stock_news_url": "https://www.marketsmojo.com/news/dr-reddys-laboratories-734514"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
      "datetime": "27-Jan-2026",
      "details": "Transcript of earnings call conducted on January 21 2026",
      "source": "BSE"
    },
    {
      "caption": "Disclosure Under Regulation 30 Of SEBI (LODR) Regulations 2015",
      "datetime": "24-Jan-2026",
      "details": "Disclosure under Regulation 30 of SEBI (LODR) Regulations 2015",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "22-Jan-2026",
      "details": "Copies of newspaper publication",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Dr Reddys Laboratories Ltd has declared <strong>800%</strong> dividend, ex-date: 10 Jul 25",
          "dt": "2025-07-10",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Dr Reddys Laboratories Ltd has announced <strong>1:5</strong> stock split, ex-date: 28 Oct 24",
          "dt": "2024-10-28",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Dr Reddys Laboratories Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 28 Aug 06",
          "dt": "2006-08-28",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Dr Reddys Laboratories Ltd Faces Downgrade Amidst Mixed Market Performance and Nifty 50 Membership Significance

2026-02-02 09:20:32

Index Membership and Market Significance

As a key member of the Nifty 50, Dr Reddys Laboratories Ltd holds considerable influence on the benchmark’s overall performance, particularly within the Pharmaceuticals & Biotechnology sector. The company’s market capitalisation stands at a robust ₹99,149.91 crores, underscoring its stature as a large-cap stock. Its inclusion in the index not only attracts passive fund flows from index-tracking funds but also places it under the scrutiny of institutional investors who closely monitor sectoral and market-wide trends.

However, the stock’s recent performance has been underwhelming relative to the Sensex and sector peers. Over the past year, Dr Reddys Laboratories has recorded a decline...

Read full news article

Dr Reddys Laboratories Ltd Faces Sell Grade Amid Mixed Performance and Nifty 50 Membership Impact

2026-02-01 09:20:58

Significance of Nifty 50 Membership

Being part of the Nifty 50 index confers considerable prestige and investment inflows for Dr Reddys Laboratories Ltd. The index membership ensures enhanced visibility among domestic and global institutional investors, often translating into higher liquidity and a more stable shareholder base. However, this status also brings heightened expectations regarding financial performance and corporate governance.

Dr Reddys, with a market capitalisation of ₹1,01,666.32 crores, is categorised as a large-cap stock, making it a key component of the index’s Pharmaceuticals & Biotechnology sector representation. The company’s inclusion in the Nifty 50 means that passive funds tracking the index must h...

Read full news article

Dr Reddys Laboratories Ltd Faces Headwinds Amid Nifty 50 Membership and Institutional Shifts

2026-01-30 09:21:08

Significance of Nifty 50 Membership

As a member of the Nifty 50, Dr Reddys Laboratories Ltd holds a pivotal role in India's benchmark equity index, which represents the top 50 companies by free-float market capitalisation on the National Stock Exchange. Inclusion in this index not only enhances the stock's visibility among domestic and international investors but also ensures substantial passive fund inflows from index-tracking mutual funds and exchange-traded funds (ETFs). This status typically provides a degree of price support and liquidity, making the stock a preferred choice for large institutional portfolios.

However, membership also brings heightened scrutiny and expectations. Dr Reddys Laboratories Ltd's recent per...

Read full news article

Dr Reddys Laboratories Ltd Faces Sell Downgrade Amid Nifty 50 Membership Significance

2026-01-29 09:20:58

Significance of Nifty 50 Membership

As a key component of the Nifty 50 index, Dr Reddys Laboratories Ltd holds a critical position in India’s equity market landscape. Inclusion in this benchmark index not only enhances the stock’s visibility among domestic and international investors but also ensures substantial liquidity and institutional interest. The company’s market capitalisation stands at a robust ₹1,00,581.30 crores, categorising it firmly as a large-cap stock. This stature typically attracts passive funds tracking the Nifty 50, thereby providing a degree of price support and stability.

However, the recent performance metrics indicate that Dr Reddys is struggling to maintain its momentum. The stock has declined by 1...

Read full news article

Dr Reddys Laboratories Ltd: Navigating Nifty 50 Membership Amid Institutional Shifts

2026-01-28 09:21:01

Index Membership: A Double-Edged Sword

Being part of the Nifty 50 index confers Dr Reddys Laboratories Ltd a prestigious status, reflecting its market capitalisation, liquidity, and sector representation. With a market cap of ₹1,03,602.67 crores, it firmly sits among India’s large-cap elite. This membership ensures substantial passive fund inflows, as index-tracking funds and ETFs allocate capital in line with the index composition. However, it also subjects the stock to heightened scrutiny and volatility linked to broader index movements.

Dr Reddys’ current valuation metrics reveal a price-to-earnings (P/E) ratio of 18.59, notably below the Pharmaceuticals & Biotechnology sector average of 32.47. This discount suggests th...

Read full news article

Dr Reddys Laboratories Ltd: Navigating Nifty 50 Membership Amid Institutional Shifts

2026-01-27 09:20:57

Significance of Nifty 50 Membership

As a constituent of the Nifty 50, Dr Reddys Laboratories Ltd holds a critical position within India’s premier equity benchmark. Inclusion in this index not only reflects the company’s market capitalisation and liquidity but also ensures substantial institutional interest, particularly from index funds and passive investors. The stock’s market cap currently stands at a robust ₹1,04,036.67 crores, categorising it firmly as a large-cap entity within the Pharmaceuticals & Biotechnology sector.

Being part of the Nifty 50 means Dr Reddys is often a bellwether for sectoral and broader market trends. Its performance can influence the sectoral index and, by extension, the overall market sentiment...

Read full news article

Dr Reddys Laboratories Ltd is Rated Sell

2026-01-25 10:10:04

Dr Reddys Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 14 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Dr Reddys Laboratories Gains 5.07%: 4 Key Factors Driving the Weekly Move

2026-01-24 16:00:08

Key Events This Week

Jan 19: Death Cross formation signals bearish trend

Jan 20: Bearish momentum intensifies amid technical downturn

Jan 21: Q3 FY26 results reveal margin pressures despite revenue resilience

Jan 22: Intraday high surge of 4.98% with strong gap up opening

Jan 23: Week closes at Rs.1,235.15 (+1.48%) outperforming Sensex

Week Open

Rs.1,175.55Read full news article

Dr Reddys Laboratories Ltd: Navigating Nifty 50 Membership Amid Mixed Performance and Institutional Shifts

2026-01-23 09:21:09

Significance of Nifty 50 Membership

Being part of the Nifty 50 index confers considerable advantages to Dr Reddys Laboratories Ltd, including enhanced visibility among domestic and global investors, increased liquidity, and inclusion in numerous index-tracking funds and ETFs. This membership not only bolsters the company’s profile but also influences trading volumes and price stability. However, it also subjects the stock to heightened scrutiny and performance expectations relative to peers within the Pharmaceuticals & Biotechnology sector and the broader market.

Recent Market Performance and Valuation

Dr Reddys Laboratories Ltd currently holds a market capitalisation of ₹1,01,587 c...

Read full news article

View All News